ReachMD

Dr. Jawed Fareed is a professor of pathology and pharmacology, and director of the Hemostasis & Thrombosis Research Unit at Loyola University Medical Center. He also serves as a consultant to the Department of Laboratory Science at Hines Veterans Administration in Hines, Illinois.

Dr. Fareed received his initial graduate training in biomedical sciences at the University of London, England, and at the University of Guelph in Ontario, Canada. His doctorate degree was completed at Loyola University Chicago in pharmacology and experimental therapeutics in 1974, and is currently pursuing research, teaching and service activities. He is professionally certified in clinical laboratory sciences and clinical chemistry. In June 1996, Dr. Fareed received the degree of Doctor Honoris Causa from the University of Bordeaux in France. He has received numerous awards from various national and international organizations.

Dr. Fareed’s main area of interest is research in the development of novel anticoagulant and antithrombotic drugs. He has devoted much of his activities to the initial studies on low molecular weight heparins and he has contributed to the development of several newer antithrombotic drugs such as hirudin and tissue factor pathway inhibitors. Currently he has embarked upon a program on objective study of newer antithrombotic drugs such as the heparinomimetics, antithrombin and anti-Xa agents and polyfunctional drugs. In addition, he has initiated a program on molecularly discussed drugs with multiple targets. More recently, he has initiated the development of an integrated program on molecular hemostasis and thrombosis. This research will focus on the genomic, proteomic and glycomic analysis with reference to the new drug development.

Dr. Fareed has a strong interest in the development of newer anticoagulants and antithrombotic drugs for cardiovascular indications. His group initiated the first clinical trials on the use of low molecular weight heparins in acute coronary syndrome. He also proposed the dosage optimization approaches for the use of low molecular weight heparins in percutaneous intervention. He has participated in the initial comparative studies on such low molecular weight heparins as Clivarine (REDUCE trial), Enoxaparin (NICE-1, NICE-4 trials), Certoparin (PARAT trial), Dalteparin (DREAM trial) and several other trials with low molecular weight heparins and GP IIb/IIIa inhibitors for percutaneous intervention. He has also worked on the optimization of such antithrombin agents as angiomax, argatroban and refludan for percutaneous intervention and bypass surgical indications. Together with intervention cardiologists in the United States, South America and Europe, he has continued to provide guidelines for the optimization of clinical protocols for the proper use of anticoagulants in interventional indications. He is a strong proponent of monitoring during interventional cardiology and strongly supports ACT guided usage of low molecular weight heparin and antithrombin drugs.

He is an author or co-author of some 500 publications in the area of antithrombotic drug pharmacology. He has authored several textbooks and has published extensively in the area of hemostasis and thrombosis. Dr. Fareed views the current progress in the field of antithrombotic drugs in critical care medicine as a major advance in healthcare, however, basic and pre-clinical studies require additional attention. In the coming years, the research that is currently undertaken in this area will have a significant impact in the management of critical care patients.

Dr. Fareed’s professional affiliations included membership of the expert panel on biologicals for the World Health Organization in Geneva, Switzerland, and consultant to various regulatory agencies. He is a recipient of several national and international awards, including Sam Natelson Award of the American Association of Clinical Chemistry in 1988, the IUA 2002 Lectureship Award and the Mario Toppo Distinguished Scientist Award in 2003. He is an elected fellow of the International Union of Angiology and the American College of Angiology. In October 1997 Dr. Fareed received the distinguished services award from the South Asian Society of Thrombosis.

Dr. Fareed is the North American Chapter Secretary for the International Union of Angiology (IUA). He also serves as the chair of the Scientific Committee of the IUA. Dr. Fareed also serves as president of the South Asian Society of Atherosclerosis and Thrombosis (SASAT). He serves as vice president of the Academy of Clinical and Applied Thrombosis and Hemostasis in Dallas, Texas, and he is an honorary member of the American Venous Forum and the Medical Academy of Erfurt, Germany. Finally, Dr. Fareed is active in the educational scientific activities of various professional societies including the IUA, American Society of Hematology, the International Society of Thrombosis and Hemostasis, and the American Heart Association.